ERBB2 and breast cancer: The amount of 111In[In]-BnDTPA-trastuzumab-NLS required for RIT of HER2-positive BC in humans may be much lower than 111In[In]-DTPA-pentetreotide or 111In[In]-DTPA-EGF due to the slower elimination and generally higher tumour uptake of radiolabeled monoclonal antibodies than radiopeptides (Reilly et al. 2000).